Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve T. Rodler, Gabriel N. Hortobágyi, Shannon L. Puhalla et al.|The Lancet Oncology|2023Cited by 103
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline <i>BRCA</i>-associated breast cancer (SWOG S1416).Priyanka Sharma, Gabriel N. Hortobágyi, Eve T. Rodler et al.|Journal of Clinical Oncology|2020Cited by 49